Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 2
1993 5
1994 3
1995 8
1996 4
1997 1
1998 2
2000 1
2001 4
2002 3
2003 1
2004 1
2006 3
2007 6
2008 4
2009 1
2010 3
2011 1
2012 2
2013 3
2014 3
2015 6
2016 4
2017 3
2018 5
2019 2
2020 5
2021 4
2022 2
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Tutt A, et al. Among authors: gutin a. Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713086 Free PMC article. Clinical Trial.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Among authors: gutin a. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.
Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A, Wenstrup RJ, Bowles KR. Pruss D, et al. Among authors: gutin a. Breast Cancer Res Treat. 2014 Aug;147(1):119-32. doi: 10.1007/s10549-014-3065-9. Epub 2014 Aug 2. Breast Cancer Res Treat. 2014. PMID: 25085752 Clinical Trial.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Abkevich V, et al. Among authors: gutin a. Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9. Br J Cancer. 2012. PMID: 23047548 Free PMC article.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L, Neff C, Solimeno C, Cogan ES, Abramson VG, Boughey JC, Falkson C, Goetz MP, Ford JM, Gradishar WJ, Jankowitz RC, Kaklamani VG, Marcom PK, Richardson AL, Storniolo AM, Tung NM, Vinayak S, Hodgson DR, Lai Z, Dearden S, Hennessy BT, Mayer EL, Mills GB, Slavin TP, Gutin A, Connolly RM, Telli ML, Stearns V, Lanchbury JS, Timms KM. Lenz L, et al. Among authors: gutin a. Breast Cancer Res Treat. 2023 Nov;202(1):191-201. doi: 10.1007/s10549-023-07046-3. Epub 2023 Aug 17. Breast Cancer Res Treat. 2023. PMID: 37589839 Free PMC article.
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors.
Mabey B, Hughes E, Kucera M, Simmons T, Hullinger B, Pederson HJ, Yehia L, Eng C, Garber J, Gary M, Gordon O, Klemp JR, Mukherjee S, Vijai J, Offit K, Olopade OI, Pruthi S, Kurian A, Robson ME, Whitworth PW, Pal T, Ratzel S, Wagner S, Lanchbury JS, Taber KJ, Slavin TP, Gutin A. Mabey B, et al. Among authors: gutin a. Genet Med. 2024 Jul;26(7):101128. doi: 10.1016/j.gim.2024.101128. Epub 2024 Jun 3. Genet Med. 2024. PMID: 38829299 Free article.
Computer simulations of prebiotic evolution.
Abkevich VI, Gutin AM, Shakhnovich EI. Abkevich VI, et al. Among authors: gutin am. Pac Symp Biocomput. 1997:27-38. Pac Symp Biocomput. 1997. PMID: 9390277 Free article.
TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition.
Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, Iliev D, Gress R, He G, Frech GC, Adams TD, Skolnick MH, Lanchbury JS, Gutin A, Hunt SC, Shattuck D. Stone S, et al. Among authors: gutin a. Hum Mol Genet. 2006 Sep 15;15(18):2709-20. doi: 10.1093/hmg/ddl204. Epub 2006 Aug 7. Hum Mol Genet. 2006. PMID: 16893906
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
Clarke LE, Warf MB, Flake DD 2nd, Hartman AR, Tahan S, Shea CR, Gerami P, Messina J, Florell SR, Wenstrup RJ, Rushton K, Roundy KM, Rock C, Roa B, Kolquist KA, Gutin A, Billings S, Leachman S. Clarke LE, et al. Among authors: gutin a. J Cutan Pathol. 2015 Apr;42(4):244-52. doi: 10.1111/cup.12475. Epub 2015 Apr 13. J Cutan Pathol. 2015. PMID: 25727210 Free PMC article.
95 results